Clarithromycin is a semi-synthetic macrolide antibiotic obtained by substitution of the hydroxyl group in position 6 by a CH30 group in the erythromycin lactonic ring. Specifically clarithromycin is 6-0-Methyl Erythromycin A.
Clarithromycin is indicated for treatment of infections due to susceptible organisms. Such infections include:
1. Lower respiratory tract infections (e.g., bronchitis, pneumonia)
2. Upper respiratory tract infections (e.g., pharyngitis, sinusitis);
3. Acute otitis media.
4. Skin and soft tissue infections (e.g., folliculitis, cellulitis, erysipelas);
5. Disseminated or localized mycobacterial infections due to Mycobacterium avium or Mycobacterium intracellular. Localized infections due to Mycobacterium chelonae, Mycobacterium fortutitum, or Mycobacterium kansasii;
6. Clarithromycin is indicated for the prevention of disseminated Mycobacterium avium complex infection in HIV-infected patients with CD4 lymphocyte counts less than or equal to 100/mm3;
7. Clarithromycin in the presence of acid suppression is also indicated for the eradication of H. pylori resulting in decreased recurrence of duodenal ulcer (see FURTHER INFORMATION).
8. Treatment of odontogenic infections.
Explore more products from our portfolio
